Novo Nordisk secured a significant legal victory against compounding pharmacies producing unauthorized versions of its weight-loss drug Wegovy and diabetes treatment Ozempic. A Texas federal judge rejected a bid by compounding pharmacies to continue producing these copycat drugs, upholding the FDA's declaration that the semaglutide shortage is over. This follows another win for Novo Nordisk against a compounding pharmacy, and similar legal actions by Eli Lilly concerning its drugs. The FDA can now pursue legal action against pharmacies making compounded semaglutide.

Prepared by Olivia Bennett and reviewed by editorial team.